The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-

Publication date: Nov 14, 2024

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we data for second boosters among individuals aged 18-

Concepts Keywords
Bnt162b2 adaptive trial
Booster COVID-19
Covid immunisation
Immunogenicity policy
Vaccinations vaccination

Semantics

Type Source Name
disease MESH COVID-19

Original Article

(Visited 1 times, 1 visits today)